Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tenofovir DF | Active Comparator | Participants received tenofovir DF 300 mg for 14 days |
|
| Tenofovir alafenamide 50 mg | Experimental | Participants received tenofovir alafenamide 50 mg for 14 days |
|
| Tenofovir alafenamide 150 mg | Experimental | Participants received tenofovir alafenamide 150 mg for 14 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tenofovir DF | Drug | Tenofovir DF tablet administered orally once daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time-weighted average change from baseline through Week 2 (DAVG2) for HIV-1 RNA (log10 copies/mL) | DAVG2 was defined as the time-weighted average between baseline value through the last available value up to week 2 minus the baseline value. | Baseline to Week 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in HIV-1 RNA (log10 copies/mL) | Baseline to Week 2 | |
| Change from baseline in CD4 cell count (cells/mm3) | Baseline to Week 2 |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford Positive Care Program | Palo Alto | California | 94304 | United States | ||
| Protocare Trials Chicago Center for Clinical Trials |
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068698 | Tenofovir |
| C442442 | tenofovir alafenamide |
| ID | Term |
|---|---|
| D063065 | Organophosphonates |
| D009943 | Organophosphorus Compounds |
| D009930 | Organic Chemicals |
| D000225 | Adenine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tenofovir alafenamide | Drug | Tenofovir alafenamide tablet(s) administered orally once daily |
|
|
| Chicago |
| Illinois |
| 60610 |
| United States |
| Rockefeller University Hospital | New York | New York | 10021 | United States |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |